Vitamin K2: Benefits, Evidence, and Who Might Need It

Vitamin K2 (menaquinones, mainly MK-4 and MK-7) is the cofactor your body uses to activate two proteins that matter in midlife: osteocalcin, which binds calcium into bone, and matrix Gla protein (MGP), which blocks calcium from depositing in artery walls. That mechanism is real and well established. What is not established is the leap the supplement industry makes from it: that swallowing K2 therefore builds bone, prevents fractures, and cleans out your arteries. Trials show K2 reliably activates these proteins — and then, over and over, fail to show it changes the outcomes that matter. The honest verdict is interesting biology, unproven outcomes, and one safety issue that is genuinely non-negotiable: vitamin K directly antagonises warfarin.

What vitamin K2 actually does in the body

Vitamin K is not one molecule. Vitamin K1 (phylloquinone) is the form in leafy greens and it dominates the Western diet. Vitamin K2 is a family of menaquinones, named by the length of their side chain — MK-4 through MK-13. Two matter commercially: MK-4, found in animal foods and made by your own tissues from K1, with a half-life measured in hours; and MK-7, made by bacteria (this is what is in natto and in most supplements), which stays in the blood far longer.

All forms do the same single job. Vitamin K is the cofactor for an enzyme called gamma-glutamyl carboxylase, which adds a carboxyl group to specific glutamate residues on a small family of proteins. That chemical step — carboxylation — is what switches those proteins on, because it gives them the negative charge they need to grip calcium ions. Without enough vitamin K, the proteins are still made, they are just made inactive.

Three of those vitamin-K-dependent proteins drive the whole story:

• Clotting factors (II, VII, IX, X) — made in the liver. This is vitamin K's original, undisputed job, and the reason warfarin exists.
• Osteocalcin — made by bone-building osteoblasts. Carboxylated osteocalcin binds calcium and hydroxyapatite in the bone matrix.
• Matrix Gla protein (MGP) — made in vessel walls and cartilage. Active MGP is one of the body's strongest local inhibitors of calcification; animals bred without it develop severe arterial calcification.

Put those two non-clotting proteins side by side and you get the marketing story: the "calcium paradox." The pitch is that K2 "directs calcium into your bones and away from your arteries," which sounds mechanistic and precise and is, at the level of biochemistry, not wrong. The problem is what happens when you test it in people.

Does vitamin K2 build bone or prevent fractures?

This is where you need to separate two very different literatures, because supplement marketing deliberately blurs them.

The Japanese MK-4 trials are drug trials, not supplement trials. In Japan, menatetrenone (MK-4) is a licensed osteoporosis drug at 45 mg a day. That is 45,000 micrograms. A typical K2 capsule on a shelf contains 100 mcg. The Japanese dose is roughly 450 times larger. Early trials at that dose, such as Shiraki's 2000 study in the Journal of Bone and Mineral Research, reported fewer vertebral fractures and preserved lumbar spine density. But the decisive test was the phase IV "OF study" (Inoue, 2009), which randomised 4,378 postmenopausal women with osteoporosis to calcium alone or calcium plus menatetrenone. Its primary endpoint — new vertebral fractures over 36 months — did not differ significantly between groups. Clinical fractures trended lower but did not reach significance. The biggest, best-powered trial of the drug dose was negative.

The Western MK-7 supplement trials contradict each other. Knapen's 2013 trial in Osteoporosis International gave 244 healthy postmenopausal women 180 mcg MK-7 or placebo for three years and found a slower decline in bone density at the lumbar spine and femoral neck. That is a genuine, well-conducted, positive result and it is the single strongest thing K2 has going for it. But in 2021, a three-year Danish trial (Rønn et al., also in Osteoporosis International) gave 142 postmenopausal women with osteopenia a higher dose — 375 mcg MK-7 — and found no difference at all: bone density fell equally in both groups, and bone turnover markers and bone microarchitecture were unchanged. A higher dose in the population with more to gain produced nothing.

And note the outcome in every one of these: bone density, a surrogate. The clinical event you care about is a broken hip or spine, and no adequately powered Western trial has shown K2 prevents one. Meta-analyses that pool the Japanese and Western data do report benefit, but they are pooling a 45 mg drug with a 180 mcg supplement across wildly different populations, and that is a weak foundation for a claim. Major osteoporosis guidelines do not list vitamin K as an established fracture-prevention agent — which is the tell. If it worked, it would be in them.

Does vitamin K2 protect your arteries?

Here the pattern is even cleaner, and even more damning for the marketing.

K2 trials reliably move the biomarker. Supplementation lowers dp-ucMGP (the inactive form of matrix Gla protein), which proves the vitamin got in and did its biochemical job. Knapen's 2015 trial in Thrombosis and Haemostasis — same cohort, 180 mcg MK-7 for three years — even found improved arterial stiffness, most noticeably in the women who started stiffest. Encouraging.

Then the harder trials arrived. AVADEC (Circulation, 2022) randomised 365 men with significant aortic valve calcification to 720 mcg MK-7 plus vitamin D or placebo for two years. dp-ucMGP dropped sharply — target engaged. Progression of aortic valve calcification, the primary endpoint: no significant difference (mean difference 17 arbitrary units, P = 0.64), and cardiovascular events were identical, 10 in each arm. Trevasc-HDK (Kidney International Reports, 2023) tested MK-7 in haemodialysis patients, the population with the most aggressive vascular calcification and therefore the most to gain. Again dp-ucMGP fell; again coronary artery calcium progression was no different at 18 months, and major cardiac events and mortality were no different either.

This is the most informative thing in the whole K2 file. When you take a supplement that hits its molecular target squarely and it still doesn't change the disease, the honest conclusion is that the mechanism, however elegant, is not the lever it was assumed to be.

The honest evidence grade, claim by claim

What about the D3 + K2 combination?

You will see this everywhere: "never take vitamin D without K2, or the calcium will end up in your arteries." It is a superb sales line — it converts one supplement purchase into two — and it is not backed by a trial. The idea is extrapolated from animal studies and from the mechanism. In humans, the trial that most closely resembles the claim, AVADEC, gave D and K2 together to men who already had calcified valves and still did not slow calcification.

Nobody has shown that vitamin D at ordinary supplemental doses causes arterial calcification in people with adequate vitamin K status, and nobody has shown that adding K2 prevents harm from vitamin D. Combined D3+K2 products are not dangerous, and if you are buying one anyway the K2 costs you little. But you are not correcting a deficiency and you are not neutralising a risk — you are buying a hypothesis. If you want the honest version of the vitamin D conversation, start with vitamin D for women, and for the pairing question specifically, vitamins you should not take together.

Where do you get K2 from food — and are you actually short?

Overt vitamin K deficiency in healthy adults is rare. Vitamin K is widespread in food, gut bacteria make menaquinones, and the body recycles the vitamin efficiently. The people who genuinely run low are those with fat malabsorption (Crohn's, coeliac, cystic fibrosis, bariatric surgery), significant liver disease, or long-term broad-spectrum antibiotic use. In the US, the Adequate Intake is 90 mcg a day for adult women — and that figure is set on phylloquinone (K1). There is no separate official requirement for K2, because no health authority has concluded you need one.

Two things follow. First, natto is the only food that delivers MK-7 at anything like supplement doses; if you eat it, you are already getting more than any capsule provides. Second, if your interest is bone, the interventions with actual fracture data are not exotic — they are calcium and vitamin D if your intake is low, progressive resistance and impact exercise, not smoking, moderate alcohol, and — where indicated — the osteoporosis medications that have been shown in large trials to cut fracture risk. K2 is not a substitute for any of that, and treating it as one is the real harm in the marketing.

The safety point almost nobody mentions: warfarin

Warfarin works by blocking vitamin K recycling. Vitamin K is therefore its direct pharmacological antagonist — this is not a theoretical interaction, it is the mechanism of the drug. Extra vitamin K, in any form including K2 supplements, can lower your INR and reduce anticoagulation; abruptly dropping vitamin K intake can push the INR up and raise bleeding risk. MK-7's long half-life makes it particularly capable of destabilising control.

If you take warfarin (Coumadin, Jantoven) or another vitamin K antagonist, do not start, stop, or change a vitamin K2 supplement without talking to the clinician who manages your INR. The goal with warfarin is not to avoid vitamin K — it is to keep your intake consistent, and to have any deliberate change managed with monitoring. This applies to K2 supplements and to a sudden new natto habit alike. Note that this interaction is specific to warfarin-type drugs; the newer direct oral anticoagulants (apixaban, rivaroxaban, dabigatran) do not work through vitamin K. You can check your own combination in our interaction checker.

Beyond warfarin, MK-7 at supplement doses has looked well tolerated in trials up to three years, and no upper limit has been set for vitamin K because toxicity from food and supplements is not seen. "Well tolerated" is not the same as "does something," though — and product quality is its own issue. K2 supplements are regulated as food, not medicine, so dose accuracy and purity depend entirely on the manufacturer. Run any product through our supplement scorecard, look for genuine third-party testing, and know how to spot a supplement recall.

When to talk to a clinician

Book a conversation — before buying anything — if any of these apply to you:

• You take warfarin or another vitamin K antagonist. Non-negotiable. Any change in vitamin K intake needs your prescriber and INR monitoring.
• You are worried about your bones. The right first step is not a capsule, it is knowing where you stand. Ask about a DEXA scan and a fracture-risk assessment, especially in the years around and after menopause when bone loss accelerates sharply.
• You have already been told you have osteopenia or osteoporosis. This is the moment to talk about interventions with fracture data behind them — not to self-treat with K2 and lose years of bone.
• You have a fat-malabsorption condition, liver disease, or have had bariatric surgery. These are the situations where vitamin K status genuinely can be low and worth checking.
• You have unexplained easy bruising or bleeding. Get it investigated rather than supplemented.

The bottom line

Vitamin K2 is a real vitamin doing a real, well-characterised job, and the calcium-paradox mechanism is one of the more genuinely interesting stories in nutrition. But a mechanism is a hypothesis, not a result. Every time K2 has been put to a hard test — fractures in a 4,378-woman trial, valve calcification in AVADEC, calcification and cardiac events in dialysis patients — it has activated its target protein and then failed to change the outcome. That is a supplement being sold with far more confidence than its data support.

If you enjoy natto or aged cheese, eat them; you are getting plenty. If you are taking a modest K2 supplement and it is cheap, it is unlikely to hurt you — unless you are on warfarin, in which case it can. But if K2 is your bone plan, you do not have a bone plan. Load your bones, get your calcium and vitamin D right, find out your actual bone density, and spend your attention on the things with fracture trials behind them. See our full bone health hub and our honest guide to the supplements aisle.